Dysregulated CD1 profile in myeloid dendritic cells in CVID is normalized by IVIg treatment.

摘要

The human organic cation transporter (OCT1) has been implicated in the uptake of imatinib into chronic myeloid leukemia (CML) cells.1"4 Moreover, OCT1 expression or activity is thought to be a critical determinant of imatinib response and is considered to predict the long-term outcome of chronic-phase CML.5"7 Assessment of OCT1 activity was derived from the intracellular uptake and retention (IUR) of imatinib with and without inhibitors such as prazosin or aman-tadine.These functional OCT1 activity assays, as originally devised by Thomas et al and later on also used by White and colleagues, solely rely on transporter inhibition.